⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for acute lymphoblastic leukemia in remission

Every month we try and update this database with for acute lymphoblastic leukemia in remission cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic LeukemiaNCT03488225
Acute Lymphobla...
B Acute Lymphob...
B Acute Lymphob...
Cyclophosphamid...
Cytarabine
Dexamethasone
Doxorubicin Hyd...
Inotuzumab Ozog...
Laboratory Biom...
Leucovorin Calc...
Mercaptopurine
Methotrexate
Ofatumumab
Prednisone
Rituximab
Vincristine Sul...
16 Years - M.D. Anderson Cancer Center
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationNCT03602898
Acute Lymphobla...
Acute Myeloid L...
Chronic Myelomo...
Chronic Phase C...
Hematopoietic a...
Myelodysplastic...
Myelofibrosis
Myeloproliferat...
Recurrent Acute...
Recurrent Hodgk...
Recurrent Non-H...
Refractory Acut...
Therapy-Related...
Anti-Thymocyte ...
Busulfan
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Methotrexate
Peripheral Bloo...
Quality-of-Life...
Questionnaire A...
Tacrolimus
Total-Body Irra...
- 65 YearsFred Hutchinson Cancer Center
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic LeukemiaNCT03488225
Acute Lymphobla...
B Acute Lymphob...
B Acute Lymphob...
Cyclophosphamid...
Cytarabine
Dexamethasone
Doxorubicin Hyd...
Inotuzumab Ozog...
Laboratory Biom...
Leucovorin Calc...
Mercaptopurine
Methotrexate
Ofatumumab
Prednisone
Rituximab
Vincristine Sul...
16 Years - M.D. Anderson Cancer Center
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic SyndromeNCT03670966
Acute Lymphobla...
Acute Myeloid L...
Acute Myeloid L...
Chronic Myelomo...
Myelodysplastic...
Recurrent Acute...
Recurrent Acute...
Refractory Acut...
Refractory Acut...
Recurrent Mixed...
Refractory Mixe...
Hematopoietic a...
Astatine At 211...
Cyclophosphamid...
Total-Body Irra...
Peripheral Bloo...
Bone Marrow Tra...
Mycophenolate M...
Recombinant Gra...
Fludarabine Pho...
Tacrolimus
Bone Marrow Asp...
Biospecimen Col...
18 Years - 75 YearsFred Hutchinson Cancer Center
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological MalignanciesNCT03885947
Hematological M...
Acute Leukemia ...
Acute Lymphobla...
Myelodysplastic...
Non-Hodgkin Lym...
Hodgkin Lymphom...
Cord blood stem...
Valproic Acid
Fludarabine
cytoxan
Thiotepa
TBI
18 Years - 65 YearsIcahn School of Medicine at Mount Sinai
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG DosingNCT05794880
Leukemia
Acute Myeloid L...
Myelodysplasia
Acute Lymphobla...
Chronic Myeloge...
Chronic Myeloge...
Chronic Myeloge...
Biphenotypic Ac...
Lymphoblastic L...
Burkitt Lymphom...
Burkitt Leukemi...
Lymphoma After ...
Other Malignant...
Magnetic-Activa...
0 Years - 25 YearsMedical College of Wisconsin
NK Cells in Cord Blood TransplantationNCT01619761
Accelerated Pha...
Acute Biphenoty...
Acute Lymphobla...
Acute Myeloid L...
Chronic Phase C...
DS Stage II Pla...
DS Stage III Pl...
High Grade B-Ce...
ISS Stage II Pl...
ISS Stage III P...
Myelodysplastic...
Recurrent Acute...
Recurrent Acute...
Recurrent Chron...
Recurrent Hodgk...
Recurrent Non-H...
Recurrent Small...
Refractory Acut...
Refractory Chro...
Refractory Hodg...
Refractory Non-...
Refractory Smal...
Secondary Acute...
Therapy-Related...
Therapy-Related...
Allogeneic Hema...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Lenalidomide
Melphalan
Mycophenolate M...
Natural Killer ...
Rituximab
Tacrolimus
Total-Body Irra...
Umbilical Cord ...
- 75 YearsM.D. Anderson Cancer Center
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHDNCT02220985
Accelerated Pha...
Acute Biphenoty...
Acute Leukemia ...
Acute Undiffere...
Allogeneic Hema...
Blast Phase Chr...
Blastic Plasmac...
Childhood Acute...
Childhood Acute...
Donor
Lymphoblastic L...
Myelodysplastic...
Myelodysplastic...
Myelodysplastic...
Recurrent Acute...
Recurrent Acute...
Recurrent Child...
Recurrent Child...
Recurrent Chron...
Refractory Acut...
Refractory Acut...
Acute Lymphobla...
Acute Myeloid L...
Allogeneic Hema...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Methotrexate
Mycophenolate M...
Peripheral Bloo...
Peripheral Bloo...
Tacrolimus
Thiotepa
Total-Body Irra...
- 60 YearsFred Hutchinson Cancer Center
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell TransplantNCT02506933
Accelerated Pha...
Acute Lymphobla...
Acute Myeloid L...
Chronic Lymphoc...
Chronic Phase C...
Cytomegaloviral...
Hodgkin Lymphom...
Lymphadenopathy
Lymphoblastic L...
Myelodysplastic...
Myelofibrosis
Myeloproliferat...
Non-Hodgkin Lym...
Laboratory Biom...
Multi-peptide C...
Placebo
18 Years - 75 YearsCity of Hope Medical Center
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic SyndromeNCT03494569
Acute Lymphobla...
Acute Lymphobla...
Acute Myeloid L...
Acute Myeloid L...
Hematopoietic C...
Minimal Residua...
Myelodysplastic...
Secondary Acute...
Fludarabine
Laboratory Biom...
Melphalan
Total Marrow Ir...
12 Years - City of Hope Medical Center
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG DosingNCT05794880
Leukemia
Acute Myeloid L...
Myelodysplasia
Acute Lymphobla...
Chronic Myeloge...
Chronic Myeloge...
Chronic Myeloge...
Biphenotypic Ac...
Lymphoblastic L...
Burkitt Lymphom...
Burkitt Leukemi...
Lymphoma After ...
Other Malignant...
Magnetic-Activa...
0 Years - 25 YearsMedical College of Wisconsin
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaNCT03096782
Accelerated Pha...
Acute Biphenoty...
Acute Leukemia
Acute Lymphobla...
Acute Lymphobla...
Acute Myeloid L...
Acute Myeloid L...
Chemotherapy-Re...
Chronic Lymphoc...
Chronic Myeloge...
Chronic Myelomo...
Hodgkin Lymphom...
Langerhans Cell...
Minimal Residua...
Myelodysplastic...
Myelodysplastic...
Non-Hodgkin Lym...
Recurrent Hodgk...
Refractory Acut...
Refractory Myel...
Small Lymphocyt...
Therapy-Related...
Anti-Thymocyte ...
Busulfan
Clofarabine
Cyclophosphamid...
Filgrastim-sndz
Fludarabine
Melphalan
Mycophenolate M...
Rituximab
Tacrolimus
Total-Body Irra...
Umbilical Cord ...
12 Years - 65 YearsM.D. Anderson Cancer Center
Allogeneic Donor Lymphocyte Infusions Combined With BlinatumomabNCT03982992
B Cell Precurso...
B-Cell Acute Ly...
Acute Lymphobla...
Acute Lymphobla...
Acute Lymphobla...
Blinatumomab in...
18 Years - Ludwig-Maximilians - University of Munich
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell TransplantNCT03438344
Accelerated Pha...
Acute Lymphobla...
Acute Myeloid L...
Bone Marrow Tra...
Chronic Lymphoc...
Chronic Phase C...
Hematopoietic C...
Hodgkin Lymphom...
Myelodysplastic...
Myelofibrosis
Myeloproliferat...
Non-Hodgkin Lym...
Multi-antigen C...
Laboratory Biom...
Placebo
18 Years - City of Hope Medical Center
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell TransplantNCT03438344
Accelerated Pha...
Acute Lymphobla...
Acute Myeloid L...
Bone Marrow Tra...
Chronic Lymphoc...
Chronic Phase C...
Hematopoietic C...
Hodgkin Lymphom...
Myelodysplastic...
Myelofibrosis
Myeloproliferat...
Non-Hodgkin Lym...
Multi-antigen C...
Laboratory Biom...
Placebo
18 Years - City of Hope Medical Center
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic SyndromesNCT01690520
Acute Biphenoty...
Acute Lymphobla...
Acute Myeloid L...
Chronic Myeloge...
Myelodysplastic...
Cyclophosphamid...
Cyclosporine
Ex Vivo-Expande...
Fludarabine Pho...
Mycophenolate M...
Thiotepa
Total-Body Irra...
Umbilical Cord ...
6 Months - 65 YearsNohla Therapeutics, Inc.
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG DosingNCT05794880
Leukemia
Acute Myeloid L...
Myelodysplasia
Acute Lymphobla...
Chronic Myeloge...
Chronic Myeloge...
Chronic Myeloge...
Biphenotypic Ac...
Lymphoblastic L...
Burkitt Lymphom...
Burkitt Leukemi...
Lymphoma After ...
Other Malignant...
Magnetic-Activa...
0 Years - 25 YearsMedical College of Wisconsin
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute LeukemiaNCT04232241
Acute Myeloid L...
Acute Lymphobla...
Myelodysplastic...
Allogeneic Stem...
18 Years - 70 YearsUniversitätsklinikum Hamburg-Eppendorf
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell TransplantNCT02506933
Accelerated Pha...
Acute Lymphobla...
Acute Myeloid L...
Chronic Lymphoc...
Chronic Phase C...
Cytomegaloviral...
Hodgkin Lymphom...
Lymphadenopathy
Lymphoblastic L...
Myelodysplastic...
Myelofibrosis
Myeloproliferat...
Non-Hodgkin Lym...
Laboratory Biom...
Multi-peptide C...
Placebo
18 Years - 75 YearsCity of Hope Medical Center
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute LeukemiaNCT04232241
Acute Myeloid L...
Acute Lymphobla...
Myelodysplastic...
Allogeneic Stem...
18 Years - 70 YearsUniversitätsklinikum Hamburg-Eppendorf
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell TransplantNCT02083250
Acute Lymphobla...
Acute Myeloid L...
Allogeneic Hema...
Myelodysplastic...
Previously Trea...
Recurrent Acute...
Recurrent Acute...
Allogeneic Bone...
Allogeneic Hema...
Anti-Thymocyte ...
Busulfan
Clofarabine
Fludarabine Pho...
Peripheral Bloo...
Pharmacological...
Vorinostat
- 60 YearsM.D. Anderson Cancer Center
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationNCT03602898
Acute Lymphobla...
Acute Myeloid L...
Chronic Myelomo...
Chronic Phase C...
Hematopoietic a...
Myelodysplastic...
Myelofibrosis
Myeloproliferat...
Recurrent Acute...
Recurrent Hodgk...
Recurrent Non-H...
Refractory Acut...
Therapy-Related...
Anti-Thymocyte ...
Busulfan
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Methotrexate
Peripheral Bloo...
Quality-of-Life...
Questionnaire A...
Tacrolimus
Total-Body Irra...
- 65 YearsFred Hutchinson Cancer Center
Allogeneic Donor Lymphocyte Infusions Combined With BlinatumomabNCT03982992
B Cell Precurso...
B-Cell Acute Ly...
Acute Lymphobla...
Acute Lymphobla...
Acute Lymphobla...
Blinatumomab in...
18 Years - Ludwig-Maximilians - University of Munich
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell TransplantNCT02083250
Acute Lymphobla...
Acute Myeloid L...
Allogeneic Hema...
Myelodysplastic...
Previously Trea...
Recurrent Acute...
Recurrent Acute...
Allogeneic Bone...
Allogeneic Hema...
Anti-Thymocyte ...
Busulfan
Clofarabine
Fludarabine Pho...
Peripheral Bloo...
Pharmacological...
Vorinostat
- 60 YearsM.D. Anderson Cancer Center
CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation TreatmentNCT05381662
Acute Lymphobla...
CD19 CAR-T cell...
18 Years - 65 YearsShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: